In August 2004, SNBL CHINA, Ltd. was established in Gao Yao City, Guang Zhou Province, China to secure a stable source of research animals. The purpose of the company is to breed, develop, quarantine, and export primates. Over the years, SNBL has cultivated new markets and acquired unrivaled expertise and know-how for pharmaceutical development research using primates.

Contract business in the preclinical research industry is growing, as development processes are increasingly outsourced due to the fierce competition in pharmaceutical development. In order to ensure safety and efficacy of new biotechnology in humans, the demand for primates in pharmaceutical development is expected to increase.

SNBL has developed a network of primate sources in locations including China and Indonesia, but to provide higher-quality research animals and to secure a more stable source, SNBL CHINA, Ltd. was established. The establishment aims to provide SNBL in Japan and US, and other companies, a secure supply of the highest-quality primates. The basis of SNBL's portfolio strategy is the establishment of a comprehensive pharmaceutical development value chain from preclinical to clinical operations around the globe. SNBL CHINA, Ltd. will be not only be the headquarters of preclinical operations in China, but also a stepping stone to establishing clinical operations.